PEPia Egerup

Pia Egerup

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pia Egerup has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Detection of microchimerism in menstrual blood: a proof-of-concept study including 86 women

    by Pia Egerup, Kilian Vomstein, Ida Behrendt-Møller, Amalie Dyhrberg Boje, Marie-Louise Bertelsen, Cecilie Sofie Eiken, Michelle Raupelyté Reiersen, David Westergaard, Sofie Dolores Holm Müller, Marianne Antonius Jakobsen, et al.

  • Open Access

    Hydroxychloroquine treatment for recurrent pregnancy loss: a study protocol for a randomized, double-blind, placebo-controlled trial

    by Anna L. Talbot, Pia Egerup, Anne L. Lunøe, Karen K. Jensen, Marie L.T. Chonovitsch, Anne-Sofie Korsholm, Ida Behrendt-Møller, Tanja S. Hartwig, David Westergaard, Kilian Vomstein, et al.

    Introduction Pregnancy loss occurs in 25% of all pregnancies. While 50-60% of the pregnancy losses are due to fetal chromosomal and structural abnormalities, incompatible with life, some of the remaining euploid pregnancy losses are likely caused by maternal conditions. At least 2% of all women suffer ≥3 consecutive pregnancy losses, defined as recurrent pregnancy loss (RPL). A hyperactive maternal immune system has been suspected to be responsible for rejection of healthy fetuses and be the underlying cause for unexplained recurrent pregnancy loss. However, very sparsely evidence-based treatment is available. The anti-inflammatory immune modulatory effects of hydroxychloroquine (HCQ) and casuistic reports of live births by women with previous RPL after HCQ-treatment, have given rise to several hypothesizes for HCQs impact on RPL. In this multicenter randomized, double-blinded, placebo-controlled trial (db-RCT) we aim to uncover whether HCQ can increase the live birth rate (LBR) in women with RPL, thus laying the foundation for an evidence-based treatment to make a real difference for a much-overlooked group of patients. Methods and analysis We will assess HCQ treatment in women with a minimum of four consecutive unexplained pregnancy losses (or three pregnancy losses including a second trimester pregnancy loss), and monitor a potential difference in LBR among women allocated treatment with HCQ and placebo, without exclusion of any included patients (Intention to treat analysis) and with exclusion of those with ectopic pregnancy, pregnancy loss due to chromosome abnormalities, neglect of treatment, induced abortion or those who withdraw from the treatment earlier than the protocol dictates (per protocol analysis). Secondary outcome measures include comparison of the rate of perinatal complications in the intervention group to the placebo group and examination of inflammatory and immunological mechanisms in peripheral blood. We aim to include 186 patients in the db-RCT. In addition, we will in a sub-study with 10 women monitor metabolic activity measured by ultra-low dose FDG-PET/CT scans before and during pregnancy. Metabolic activity correlates with grade of inflammation and will be measured in the uterus and immune-related tissue such as bone marrow, spleen, thymus, and lymph nodes. Ethics and Dissemination The db-RCT including the PET/CT sub-study has been approved by The Regional Committee on Health Research Ethics, The Danish Medicines Agency, The Danish Data Protection Agency, and transferred to The Center for Data handling Capital Region of Denmark in May 2024. The trial conforms to good clinical practice guidelines (GCP) and has been registered at ClinicalTrials.gov (ClinicalTrials.gov ID NCT03305263). Findings will be disseminated through peer-reviewed journals and at professional conferences. Strengths and limitations of this study Assessment of HCQ treatment in women with RPL to potentially increase LBR. Assessment of the rate of perinatal outcomes associability with HCQ treatment. RPL trials so far have struggled to obtain pregnancy tissue from PL and if obtained been severely contaminated with maternal tissue. We will use circulating cell-free fetal DNA (cffDNA), isolated from maternal peripheral blood for fetal genetic diagnostics as we demonstrated feasible in our recent Lancet publication. Non-invasive monitoring of inflammation in the uterus before and during pregnancy by the means of ultra-low dose PET/CT scans.

  • Open Access

    Pregnancy Loss and the Risk of Myocardial Infarction, Stroke, and All‐Cause Mortality: A Nationwide Partner Comparison Cohort Study

    by Anders Pretzmann Mikkelsen, Pia Egerup, Astrid Marie Kolte, David Westergaard, Christian Torp‐Pedersen, Henriette Svarre Nielsen, Øjvind Lidegaard

    Background: Pregnancy loss has been associated with myocardial infarction, stroke, and all‐cause mortality in women through unknown mechanisms. The aim of this study was to examine these associations in women and their male partners. Methods and Results: In this register‐based cohort study, all people born between 1957 and 1997, residing in Denmark between 1977 and 2017, and with a registered partner of the opposite sex were eligible for inclusion. Male partners through cohabitation, marriage, or paternity constituted the male cohort. Exposure to pregnancy loss was categorized as follows: 0, 1, 2, or ≥3 pregnancy losses. The outcomes of interest were myocardial infarction, stroke, and all‐cause mortality. The Cox proportional hazards model estimated hazard ratios (HRs), adjusted for age, calendar year, parity, and parental history of myocardial infarction or stroke. During follow‐up, 1 112 507 women experienced 4463 events of myocardial infarction compared with 13 838 events among 1 120 029 male partners. With the no pregnancy loss group as reference, the adjusted HRs of myocardial infarction in the female cohort after 1, 2, and ≥3 pregnancy losses were as follows: 1.1 (95% CI, 1.0–1.2), 1.3 (95% CI, 1.1–1.5), and 1.4 (95% CI, 1.1–1.8), respectively. In the male partner cohort, the corresponding estimates were 1.0 (95% CI, 1.0–1.1), 1.1 (95% CI, 1.0–1.2), and 1.0 (95% CI, 0.8–1.2), respectively. The outcome of stroke showed similar results. Pregnancy loss was not significantly associated with increased mortality in either sex. Conclusions: Pregnancy loss or stillbirth was significantly associated with myocardial infarction and stroke in women but not their male partners. Pregnancy loss or stillbirth was not significantly associated with all‐cause mortality in women or male partners.


  • Endometriosis is associated with pregnancy loss: a nationwide historical cohort study

    by Amalie Dyhrberg Boje, Pia Egerup, David Westergaard, Marie-Louise Mathilde Friis Bertelsen, Mette Nyegaard, Dorthe Hartwell, Øjvind Lidegaard, Henriette Svarre Nielsen


  • Open Access

    Live Birth Rate in Women with Recurrent Pregnancy Loss after In Vitro Fertilization with Concomitant Intravenous Immunoglobulin and Prednisone

    by Pia Egerup, Henriette Svarre Nielsen, Anders Nyboe Andersen, Ole Bjarne Christiansen

    Pregnancy loss after in vitro fertilization (IVF) is at least as common as after spontaneous conception. Recurrent pregnancy loss (RPL) may often have an immunological background, and it is therefore relevant to test immune-based interventions in these patients. The objective was to investigate the effect of immunotherapy with intravenous immunoglobulin (IvIg) and prednisone (PRS) as concomitant therapy to IVF in women with RPL after earlier IVF treatments. In a cohort study conducted at The Danish RPL Clinic, 41 women with three or more consecutive pregnancy losses after IVF underwent at least one further IVF cycle with concomitant immunotherapy from 2012 to 2017. The immunotherapy with IvIg and PRS was given before embryo transfer and repeatedly in the first trimester when pregnancy was achieved. Fourteen women (34.2%) achieved a live birth after the first embryo transfer with immunotherapy, and a total of 32/41 (78%) achieved a live birth after up to 4 embryo transfers. Baseline characteristics and the presence of autoantibodies were not significantly different among women achieving live birth or not. The observed 34% birth rate in women with RPL after IVF receiving immunotherapy appears higher than the expected 16–19% birth rate without immunotherapy and is similar to findings in a previous cohort from our clinic. Concomitant immunotherapy as described may be a promising intervention for women with RPL after IVF; however, the effect must be tested in a randomized controlled trial.


  • Open Access

    Pregnancy Loss and Cardiovascular Disease: A Nationwide Cohort Study

    by Anders P. Mikkelsen, Pia Egerup, Astrid M. Kolte, David Westergaard, Christian Torp-Pedersen, Henriette S. Nielsen, Øjvind Lidegaard

    Objectives To examine how pregnancy loss influences the risk of cardiovascular disease later in life. Design Prospective historical cohort study. Setting Danish nationwide health registries. Participants All Danish women with a recorded pregnancy from 1977 to 2017. Main outcome measures Venous thromboembolism, myocardial infarction, or ischemic stroke. Results In this two-part study, part one evaluated the 20-year absolute risk of cardiovascular disease from age 40 among 596,699 women with a full registered reproductive history. Adjusting for calendar year, diabetes, autoimmune disease, live births, and education, the absolute risk of an outcome after 0 and ≥4 pregnancy losses, respectably was: venous thromboembolism 3.0% (95% CI 2.8 to 3.2%) and 5.0% (3.4 to 6.8%); myocardial infarction 1.5% (1.4 to 1.6%) and 2.4% (1.4 to 3.6%); ischemic stroke 2.0% (1.9 to 2.1%) and 2.6% (1.5 to 3.6%). Prior stillbirth increased the absolute risk of later venous thromboembolism by 1.1% (0.2 to 2.3%); myocardial infarction by 1.1% (0.3 to 2.0%). In study part two, we included 966,490 women from first pregnancy in a time-dependent Cox regression model. Adjusted for confounders, each additional pregnancy loss increased the hazard ratio of venous thromboembolism 1.10 (95% CI 1.07 to 1.13); myocardial infarction 1.12 (1.07 to 1.18); and ischemic stroke 1.10 (1.06 to 1.14). Stillbirth was strongly associated with myocardial infarction before age 40, adjusted hazard ratio of 4.60 (2.65 to 8.00). Conclusion Pregnancy loss was associated with later venous thromboembolism, myocardial infarction, and ischemic stroke. The absolute and relative risk of outcomes increased in a dose-response manner with increasing numbers of prior pregnancy losses. Stillbirth was strongly associated with myocardial infarction before age 40.

  • Open Access

    Increased risk of neonatal complications and infections in children of kidney-transplanted women: A nationwide controlled cohort study

    by Pia Egerup, Nicholas Carlson, Louise Bruun Oestergaard, Paul Blanche, James R. Scott, Mads Hornum, Christian Torp-Pedersen, Ole Bjarne Christiansen


  • Pregnancy loss is associated with type 2 diabetes: a nationwide case–control study

    by Pia Egerup, Anders P. Mikkelsen, Astrid Marie Kolte, David Westergaard, Steen Rasmussen, Filip K. Knop, Øjvind Lidegaard, Henriette S. Nielsen

    Aims/hypothesis Type 2 diabetes is killing more people than ever, and early-life predictors remain critical for the development of effective preventive strategies. Pregnancy loss is a common event associated with later atherosclerotic disease and ischaemic heart failure and might constitute a predictor for type 2 diabetes. The objective of this study was to investigate whether pregnancy loss is associated with later development of type 2 diabetes. Methods Using a Danish nationwide cohort, we identified all women born from 1957 through to 1997 and who had a diagnosis of type 2 diabetes during the period 1977 to 2017. The women were matched 1:10 on year of birth and educational level to women without diabetes in the general Danish population. Conditional logistic regression models provided odds ratios for type 2 diabetes with different numbers of pregnancy losses. Results We identified 24,774 women with type 2 diabetes and selected 247,740 controls without diabetes. Women who had ever been pregnant (ever-pregnant women) with 1, 2 and ≥ 3 pregnancy losses had ORs of type 2 diabetes of 1.18 (95% CI 1.13, 1.23), 1.38 (95% CI 1.27, 1.49) and 1.71 (95% CI 1.53, 1.92) compared with ever-pregnant women with no pregnancy losses, respectively. Women who never achieved a pregnancy had an OR of type 2 diabetes of 1.56 (95% CI 1.51, 1.61) compared with ever-pregnant women with any number of losses. Similar results were found after adjustment for obesity and gestational diabetes. Conclusions/interpretation We found a significant and consistent association between pregnancy loss and later type 2 diabetes that increased with increasing number of losses. Thus, pregnancy loss and recurrent pregnancy loss are significant risk factors for later type 2 diabetes. Future studies should explore whether this association is due to common background factors or whether prediabetic metabolic conditions are responsible for this association. Graphical abstract


  • Pregnancy loss: A 40‐year nationwide assessment

    by Øjvind Lidegaard, Anders P. Mikkelsen, Pia Egerup, Astrid M. Kolte, Steen Christian Rasmussen, Henriette S. Nielsen

    Introduction: Pregnancy loss is frequent. We aimed to assess the frequency and trends in pregnancy losses according to female age and mode of conception over a 40‐year follow‐up period.Material and methods: In a national historical prospective cohort study, we followed all Danish women 10‐49 years over the 40‐year study period 1978‐2017. Data on pregnancies and their outcomes were obtained from the National Health Registry, the Medical Birth Registry and the National Fertility Registry. Incidence rates per 100 pregnancies and per 1,000 women‐years as well as lifetime risks per 100 women were calculated. Women included in the lifetime analysis were followed from age 12 to age 49. Pregnancy loss included spontaneous abortion, missed abortion and anembryonic pregnancy.Results: In 3 519 455 recorded pregnancies, 337 008, or 9.6%, were diagnosed with a pregnancy loss. The proportion increased from 7.5% in 1978‐1979, peaked at 10.7% in 2000 and thereafter decreased to 9.1% in 2015‐2017. Pregnancy loss rate in women 10‐14 years was 3.9%, increasing gradually with age to 26.9% in pregnant women 45‐49 years, a 6.9‐fold increase. Loss rates were slightly lower in naturally conceived pregnancies than in assisted pregnancies except for women above 45 years, where the risk of loss was higher in the spontaneously conceived group. Lifetime risk of specific numbers of losses were: 0: 76.9%, 1: 17.9%, 2: 3.9%, 3: 0.87%, and 4+: 0.35%.Conclusions: The proportion of women experiencing pregnancy loss has changed little throughout four decades and is still primarily influenced by female age. More than 75% of pregnant women are never recorded with a pregnancy loss, and <1.5% will experience three or more losses.


  • Open Access

    Pregnancy Loss and Cancer Risk: A Nationwide Observational Study

    by Anders P. Mikkelsen, Pia Egerup, Julie F.M. Ebert, Astrid M. Kolte, Henriette S. Nielsen, Øjvind Lidegaard